Patients challenge Myriad Genetics for access to their gene data Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, May 21, 2016

Patients challenge Myriad Genetics for access to their gene data



news


Genetic testing company Myriad Genetics, the defendant in a landmark Supreme Court case over gene patents, is back in the spotlight — this time, for withholding genetic data from patients.
Myriad held patents on the BRCA1 and BRCA2 genes until 2013, and tested more than 1 million patients for variations in those genes that might increase a person’s risk of breast, ovarian, prostate, and other cancers.
Though Myriad no longer holds the patents on those genes, it still holds patients’ data, and has been resistant to sharing it with researchers or public databases....

0 comments :

Post a Comment

Your comments?